Key facts
- It has raised $150.0M; the latest was Later Stage VC ($50.0M) in Nov 2024.
- Notable investors include Khosla Ventures, GV, TA Ventures, Sands Capital, First Spark Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Vitara
- ·The full record, as it builds
Funding rounds
No funding rounds for Vitara are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vitara
Developer of a therapeutic platform intended to support premature infants. The company offers natural physiological processes and a fluid-filled environment that mimics natural fetal conditions, and biologically inspired protective care to protect extremely premature newborns during their early growth outside the womb, enabling neonatal clinicians and families to improve the chances of survival and reduce long-term health complications for the fragile infants.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2019
- Employees
- 44
- Website
- vitara.com/
- Ownership
- Privately Held (backing)
Vitara doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vitara shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vitara in its N-PORT filings yet. We sweep new filings monthly.